Outcome of the Meeting of Board of Directors held on Tuesday, 02nd September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genpharmasec Ltd's Board of Directors met on 2 September 2025 and approved several key items. The 33rd Annual General Meeting (AGM) has been scheduled for 29 September 2025 at 11:00 AM via video conferencing, with the e-voting window open from 26 to 28 September 2025 and a cut-off date of 22 September 2025. The Board approved the Director's Report and Annual Report for FY 2024-25, and fixed the share transfer book closure from 23 September to 29 September 2025. A new statutory auditor, M/s. Bilimoria Mehta & Co., has been appointed for a 5-year term (FY 2025-26 to 2029-30), replacing M/s. Abhishek S Tiwari & Associates whose term ends at the 33rd AGM. Additionally, the remuneration of Mr. Sohan Chaturvedi, Whole Time Director & CFO, has been revised effective 1 October 2025, and Material Related Party Transactions have been recommended for shareholder approval.
Routine AGM-related approvals with two notable items for shareholders: a change in statutory auditor (a normal governance rotation) and a proposed increase in CFO remuneration subject to shareholder vote. The material related party transactions requiring shareholder approval could draw attention at the AGM.